Against steep odds and well-established paradigms, these four companies have successfully been commercializing their products ...

Though nerves abound for funders and founders in the industry, money continues to flow into startups, sometimes in ...

Under the Inflation Reduction Act, medications with the same active ingredient will be treated as the same drug for price ...

The FDA’s dramatic summer continues to unfold as news broke late Tuesday evening that Vinay Prasad will depart the agency, ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

CEO Rob Davis referred to the cost reduction program as a “reallocation” rather than a cut, with the savings to be reinvested ...

In a surprise double announcement Tuesday, Novo reduced sales guidance by 5%—attributing the change to slowed growth of its ...

Six weeks after HHS Secretary RFK Jr. cited unexplained conflicts of interest in dismissing all 17 members of the CDC’s vaccine advisory committee, Democrats are asking for details.

While some analysts forecasted the tariffs could mean billions in additional industry expenditure, others expect the overall ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

Year-over-year BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the first quarter of 2025.

The swift FDA action removes an overhang from Sarepta and allows Elevidys to return to the market without another safety ...